Michael Deem Email & Phone Number

Michael Deem is Managing Partner at Angeliki Fund, a physical and digital private equity infrastructure fund. Michael is a former Entrepreneur in Residence at Khosla Ventures.Michael Deem was the 3rd person and performed all the original engineering calculations at Ion Torrent Systems (sold to ThermoFisher for $2.3B in 2014). He was the 10th person and director of drug design at CuraGen ($100M IPO in 1998). He started the first `Synthetic Biology' PhD program in the US.He is also General Partner at SmartHealth Catalyzer. Michael's intellectual bandwidth has benefited companies from a wide cross section of industries that include Life Sciences, Artificial Intelligence, Genomics, Data Science, Biotechnology, Energy, and Cancer Research. Michael was Department Chair of Bioengineering at Rice University. In this capacity, he oversaw a department with 20 tenure track faculty, 5 non-tenure track faculty and instructors, 20 support and research staff, 200 undergraduate and 125 graduate students, and an annual research and operating budget of approximately $27 million. The faculty represent a broad range of disciplines in bioengineering: basic physics of biology and cancer, synthetic and systems biology, multimodal imaging, machine learning, tissue engineering, and biomaterials. The department is consistently ranked in the top 10 programs in Biomedical Engineering. Michael is an active member of The National Association of Corporate Directors (NACD), and is available for select Board appointments. Certified by SAFe in Lean Portfolio Management, Agile, and Scrum.INDEPENDENT DIRECTOR• Experience on 12 Boards, Advisory Boards, and Advisor capacities. • Ion Torrent Systems, sold in 2014 for $2.3 billion• Biomedical Engineering Society, $75m revenue non-profit• Sengent, financial modeling software, sold for $40 million • CuraGen, $100M IPO in 1998• NACD (National Association of Corporate Directors) Directorship Certification, and Board Leadership FellowOPERATING PARTNER• Deep expertise in multiple, medically-related sectors enable him to be an Operating Partner, overseeing and selecting investment companies for Private Equity and Venture Capital companies.CEO | CTO | ADVISOR | Venture Capital• The scope and intellectual capacity of the educational organizations he successfully led, enable and qualify Mike for CEO engagements.https://www.linkedin.com/in/MichaelDeem

Listed skills include Leadership, Cancer Research, Research And Development, Public Speaking, and 55 others.